(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of 62.04% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Lenz Therapeutics's revenue in 2026 is $21,475,000.On average, 9 Wall Street analysts forecast LENZ's revenue for 2026 to be $544,451,704, with the lowest LENZ revenue forecast at $421,221,118, and the highest LENZ revenue forecast at $682,921,155. On average, 9 Wall Street analysts forecast LENZ's revenue for 2027 to be $1,377,813,461, with the lowest LENZ revenue forecast at $862,174,212, and the highest LENZ revenue forecast at $2,474,352,011.
In 2028, LENZ is forecast to generate $3,019,432,122 in revenue, with the lowest revenue forecast at $1,231,677,446 and the highest revenue forecast at $5,938,444,827.